Jennifer van Zelm
DEcision Support Tool IN Endovascular therapy (DESTINE) - DESTINE Health Inc.
DESTINE Health Inc. has created an innovative decision support tool used by healthcare administrators/system planners in order to create and optimize transport protocols for acute stroke patients. The tool is a cloud-based software, which is regionally customized to each healthcare jurisdiction’s unique geography and hospital treatment capabilities and efficiency. The output of the tool is a colour-coded map which displays the best transport plan (first hospital destination) for patients with suspected severe stroke, in order to optimize patient outcomes on a population level.
Infant Massage in Neonatal Withdrawal from Opioids
The role of this infant massage intervention has the potential benefits for the infants and parents in NICU. Most research reports to be mainly focusing on infant and less outcomes towards the effects on parents particularly the mothers. In view of of the promotion of health and safety for the population we cared for, this infant massage therapy will be proposed as an adjunct therapy in the management of pain in neonates that potentially experiencing withdrawal from the opioids. The institution
where the author is currently practicing has numerous numbers of patients exposed or receiving opioids.
The positive effect of this infant massage to potential withdrawal from opioids as a results in an unsettled infant who is difficult to console which thwarts maternal-infant bonding leading to a failure of the normal mother-infant bonding with adverse consequences for the infant’s growth and development. Reduces maternal anxiety and increased satisfaction. This could calm the infants and eventually reduce the increasing opioids used in NICU.
Armida Dela Cruz
Violetta Kryshtal Viktorovna
A Dream of Health as A Universal Knowledge
This dream started with the fact that chronic diseases are rapidly increasing, life expectancy has been decreasing, and the enormous number of preventable deaths that still happening due to lack of basic life support by bystanders. It aims to implement health education as a mandatory knowledge for all the population, focussing on the prevention, something that should have been done a long time ago and that may have avoided COVID19 crisis that all the world is suffering. A dream of future generations where health can be more than just an option.
Pneumoscope: An Intelligent Stethoscope for the Diagnosis of Lung Diseases
Dwarfs -Educational Kit about Emotions for Children with ASD (Autism Spectrum Disorder)
Dwarfs is an educational kit about emotions for children with ASD (autism spectrum disorder). It targets 6 - 12 years old ASD children who are educated in ordinary schools. It involves a playing process with a social worker to educate the children about emotion expression and emotion control. In the design, elements of colour, form and sound respectively trigger visual, tactile and auditory sensation of the children, so Dwarfs acts as a new platform for the children to have more and deeper communication with the social workers instead of only verbal communication since many ASD children are not good at verbal communication. The ultimate goal is to improve the social skills and social lives of ASD children. Digital programming and RFID technology are also applied on the design to provide a complete user experience for the social workers and ASD children.
Man Wai Wong
The World’s First Blood Test to Guide Treatment Decision in Prostate Cancer
Widespread use of PSA testing has led to the problem of over-treatment in prostate cancer. Many identified cancers are low-risk, clinically harmless, and do not require radical therapy. Patients with indolent prostate cancer can avoid the complications and risks associated with radiation therapy or surgery like erectile dysfunction, infection and incontinence. These patients are best managed by conservative approaches, such as “active surveillance” (annual follow up with no surgery). Lack of clear criteria defining who can be managed non-invasively forces the doctors and patients to make arbitrary decisions. We identified new molecules in the blood that can be measured to accurately distinguish aggressive from indolent prostate cancers. Our new test is the first worldwide non-invasive blood test that can accurately guide treatment decisions in prostate cancer. It uses a patented analysis and has been successfully validated in two independent cohorts. It can be used to replace the invasive biopsy for following up patients managed by active surveillance. Funding is urgently needed to finalize the standardization and optimization of the testing procedure (sample volume, storage, controls etc.) for clinical deployment. The test will greatly improve the quality of life of patients with prostate cancer by informing the decision-making and reducing the incidence of complications associated with the trans-rectal prostate biopsies.